Abbott Laboratories (ABT) Share-based Compensation (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Share-based Compensation data on file, last reported at $317.0 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 9.69% year-over-year to $317.0 million; the trailing twelve-month figure through Mar 2026 stood at $692.0 million (up 5.17% YoY), and the FY2025 full-year result was $664.0 million, down 1.34% from the prior year.
• Share-based Compensation climbed to $317.0 million in Q1 2026, from $113.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $317.0 million in Q1 2026 to a low of $111.0 million in Q4 2024.
• A 5-year average of $175.5 million and a median of $132.0 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation slumped 77.98% in 2022 and increased 9.69% in 2026, its largest moves.
• Tracing ABT's Share-based Compensation over 5 years: stood at $115.0 million in 2022, then decreased by 0.87% to $114.0 million in 2023, then slipped by 2.63% to $111.0 million in 2024, then advanced by 1.8% to $113.0 million in 2025, then jumped by 180.53% to $317.0 million in 2026.
• Business Quant data shows ABT's Share-based Compensation at $317.0 million in Q1 2026, $113.0 million in Q4 2025, and $120.0 million in Q3 2025.